Trials / Completed
CompletedNCT00714116
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBI-087 | Single IV or SC dose of SBI-087 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2008-07-14
- Last updated
- 2018-12-07
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00714116. Inclusion in this directory is not an endorsement.